Ki67 assessment in breast cancer: an update
Ki67 assessment in breast cancer: an update
复制标题
DOI：
10.1016/j.pathol.2016.11.006
复制
发表时间：
2017-02-01
期刊：
影响因子：
4.5
通讯作者：
Radosevic-Robin, Nina
中科院分区：
文献类型：
--
作者：
Penault-Llorca, Frederique;Radosevic-Robin, Nina
尽管Ki 67抗原的免疫组织化学检测已用于评估癌症增殖多年，但仍不建议将该标记物常规用于乳腺癌的临床管理。这种情况的主要原因是缺乏Ki 67评估的标准化程序，以及关于Ki 67测定解释和标记物的临床实用性的几个争论问题的持续存在。目前Ki 67评估主要用于估计预后和指导辅助治疗选择的决定，以及用于预测ER+/HER 2-乳腺癌对新辅助治疗的反应。在ER-/HER 2+和ER-/HER 2-肿瘤中，新辅助治疗后高Ki 67指数与不良预后相关。我们在这里审查影响Ki 67免疫组化检测的分析有效性的因素，其临床实用性的证据和目前的建议，其在乳腺癌管理中的使用。
Although immunohistochemical detection of the Ki67 antigen has been used for many years to assess cancer proliferation, this marker is still not recommended for routine use in clinical management of breast cancer. The major reason for this situation is a lack of a standardised procedure for Ki67 assessment as well as persistence of several issues of debate with regards to the Ki67 assay interpretation and the marker's clinical utility. Nowadays Ki67 assessment is principally used for estimation of prognosis and guiding the decision on adjuvant treatment choice, as well as for prediction of response to neoadjuvant treatment in ER+/HER2-breast cancer. In ER-/HER2+ and ER-/HER2-tumours, high post-neoadjuvant Ki67 index is associated with unfavourable prognosis. We review here the elements impacting analytical validity of the Ki67 immunohistochemical assay, the evidence of its clinical utility and the current recommendations for its use in breast cancer management.